A challenging case of fungating malignant melanoma
Krishna Mohan Baradhi
Corresponding author: Krishna Mohan Baradhi, Division of Nephrology, University of Oklahoma, Tulsa, USA
Received: 12 May 2018 - Accepted: 15 Nov 2018 - Published: 22 Nov 2018
Domain: Dermatology,Oncology,Public health
Keywords: Melanoma, UV light, immunotherapy, skin cancer
©Krishna Mohan Baradhi et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cite this article: Krishna Mohan Baradhi et al. A challenging case of fungating malignant melanoma. Pan African Medical Journal. 2018;31:204. [doi: 10.11604/pamj.2018.31.204.16050]
Available online at: https://www.panafrican-med-journal.com//content/article/31/204/full
A challenging case of fungating malignant melanoma
Krishna Mohan Baradhi1,&
1Division of Nephrology, University of Oklahoma, Tulsa, USA
&Corresponding author
Krishna Mohan Baradhi, Division of Nephrology, University of Oklahoma, Tulsa,
USA
We present the case of a 43-yearr-old male present with left arm pain from a football-sized mass over his left shoulder and arm. He had a history of 3cm melanoma on his left back 3 years ago and underwent resection and adjuvant radiation. However, he had recurrence of melanoma a year later with metastases to the left supra clavicular lymph nodes. He underwent further resection followed by multiple regimens of chemotherapy, which included vemurafenib, dabrafenib and trametinib. Unfortunately, his melanoma was aggressive and remained refractory to the currently available standard therapies. Physical examination as visualized in the figure. The patient eventually opted for a palliative total upper extremity amputation including shoulder joint. World Health Organization estimates around 132,000 new cases of melanoma are diagnosed globally every year. Melanoma is the fifth leading cancer in males and seventh leading cancer in females in the United States. Melanoma is deadliest of all skin cancers and its incidence continues to rise. While recent targeted immunotherapies have improved the survival period of melanoma, metastatic melanoma can be fatal even with the currently available therapies. The single most important preventive measure is to avoid excessive ultraviolet radiation and there should be heightened awareness of its risk factors among both clinicians and patients. Patient's education on prevention and early recognition are paramount for battling melanoma and for better outcomes. Novel biological therapies have undoubtedly made substantial progress and will likely change the landscape in the treatment of melanoma in the near future.
Figure 1: malignant
melanoma 18 x 10 cm along the lateral aspect of left nipple
extending cranio-caudally from inferior aspect of shoulder
to elbow joint